A. Steagall

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

M. Socinski, H. Gillenwater, A. Steagall, 1999, Cancer investigation.

A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.

T. Shea, S. Bernard, M. Brecher, 1995, Seminars in oncology.

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.

M. Socinski, P. Lawrence, P. Mudd, 1998, Anti-cancer drugs.

Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.

M. Socinski, J. Rosenman, J. Halle, 1997, Seminars in oncology.

A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies

T. Morgan, P. Rosen, H. Ozer, 1991 .

A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies.

T. Morgan, P. Rosen, H. Ozer, 1991, Medical and pediatric oncology.